Beigene, Ltd. (NASDAQ:ONC - Get Free Report) COO Xiaobin Wu sold 1,934 shares of the company's stock in a transaction on Friday, June 6th. The shares were sold at an average price of $253.15, for a total value of $489,592.10. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Xiaobin Wu also recently made the following trade(s):
- On Tuesday, April 1st, Xiaobin Wu sold 51,921 shares of Beigene stock. The shares were sold at an average price of $281.40, for a total value of $14,610,569.40.
Beigene Price Performance
Shares of NASDAQ:ONC traded down $6.90 during trading on Friday, reaching $269.63. The company had a trading volume of 391,727 shares, compared to its average volume of 451,056. The company has a market cap of $31.92 billion, a price-to-earnings ratio of -32.72, a price-to-earnings-growth ratio of 7.73 and a beta of 0.30. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. The firm's fifty day moving average price is $240.18. Beigene, Ltd. has a fifty-two week low of $141.31 and a fifty-two week high of $287.88.
Beigene (NASDAQ:ONC - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.12 billion. On average, equities analysts anticipate that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.
Analyst Ratings Changes
A number of research firms have issued reports on ONC. Bank of America raised Beigene from a "neutral" rating to a "buy" rating and raised their target price for the stock from $207.00 to $320.00 in a research report on Monday, March 3rd. Royal Bank of Canada lowered their price target on Beigene from $312.00 to $311.00 and set an "outperform" rating for the company in a research report on Thursday, May 8th. Wall Street Zen upgraded Beigene from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. JPMorgan Chase & Co. lifted their price objective on Beigene from $311.00 to $317.00 and gave the stock an "overweight" rating in a report on Monday, April 21st. Finally, Guggenheim boosted their price target on Beigene from $348.00 to $350.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Beigene presently has an average rating of "Buy" and an average target price of $319.00.
Get Our Latest Stock Report on ONC
About Beigene
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Read More
Before you consider BeOne Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.
While BeOne Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
